secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXOZYMES INC. (EXOZ)
CIK:        0002010788
Form:       8-K
Filed at:   2026-06-25T23:36:23+00:00
Accession:  0001493152-26-030205
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

eXoZymes receives $2M NIH Phase IIB SBIR grant for cannabinoid analog drug discovery
--------------------------------------------------------------------------------

- NIH NIGMS Phase IIB SBIR grant of $2,028,518 to support development of rare cannabinoids and engineered analogs.
- Work on two-year grant begins July 1, 2026; total non-dilutive funding now ~$19.7M.
- Grant adds a second biosolution to eXoZymes' pipeline after NCT, targeting pharmaceutical partnerships.
- U.S. minor cannabinoids market forecast to grow from $11.5B (2023) to $33.3B (2030) at ~15% CAGR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2010788/000149315226030205/0001493152-26-030205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2010788/000149315226030205/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-030205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer